Correlation Between Virpax Pharmaceuticals and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virpax Pharmaceuticals and Novo Nordisk AS, you can compare the effects of market volatilities on Virpax Pharmaceuticals and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and Novo Nordisk.

Diversification Opportunities for Virpax Pharmaceuticals and Novo Nordisk

0.39

Correlation Coefficient

Virpax Pharmaceuticals  Novo Nordisk

Weak diversification

The 3 months correlation between Virpax and Novo is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and Novo Nordisk go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and Novo Nordisk

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to generate 2.88 times more return on investment than Novo Nordisk. However, Virpax Pharmaceuticals is 2.88 times more volatile than Novo Nordisk AS. It trades about -0.01 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.14 per unit of risk. If you would invest  50.00  in Virpax Pharmaceuticals on October 5, 2024 and sell it today you would lose (12.00) from holding Virpax Pharmaceuticals or give up 24.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Virpax Pharmaceuticals  vs.  Novo Nordisk AS

Virpax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Virpax Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Novo Nordisk AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with Virpax Pharmaceuticals and Novo Nordisk

The main advantage of trading using opposite Virpax Pharmaceuticals and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind Virpax Pharmaceuticals and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.